Revised NBIO to acquire MVF
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Monash IVF Group Limited has received a revised non-binding indicative proposal to acquire the company from a consortium, which includes Genesis Capital and WHSP Holdings, at a specified cash price per share. This proposal follows a previous offer that was rejected and is subject to several conditions, including due diligence and board approval. The board is currently assessing the proposal with the help of financial and legal advisers, and shareholders are advised not to take any action at this time.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Monash IVF
- 1H26 Results Presentation
- MVF delivers 1H26 Underlying NPAT of $10.4m
- 1H26 Appendix 4D and Financial Report
- NBIO withdrawn to acquire Monash IVF
- Monash IVF rejects NBIO proposal to acquire MVF
Later from Monash IVF
- Monash IVF rejects revised non-binding indicative proposal
- Trading update
- FY2026 Results release postponed to 31 August 2026
- MVF FY26 Appendix 4E and Financial Report
- MVF FY26 Results Announcement
Follow Monash IVF into a list and get an email when it puts out news.
Follow Monash IVF